Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland

被引：0
|
作者：
Pardo, E. [1 ]
Barbier, M. [2 ]
Panje, C. [3 ]
Gautschi, O. [4 ]
Lupatsch, J. [5 ]
机构：
[1] Canton Hosp Lucerne, Med Oncol, Internal Med, Luzern, Switzerland
[2] Univ Basel, Inst Pharmaceut Med Ecpm, Basel, Switzerland
[3] Cantonal Hosp St Gallen, Radiat Oncol, St Gallen, Switzerland
[4] Canton Hosp Lucerne, Luzern, Switzerland
[5] Univ Basel, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
cost-effectiveness; Pembrolizumab; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.03
引用
收藏
页码：S992 / S992
页数：1
相关论文
共 50 条
  • [31] Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
    Wang, H.
    Agulnik, J.
    Kasymjanova, G.
    Fiset, P.
    Camilleri-Broet, S.
    Redpath, M.
    Small, D.
    Cohen, V.
    Spatz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S763 - S764
  • [32] DCVAC/LuCa with chemotherapy in patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations: Five-year survival update
    Ling, X.
    Zhong, R.
    Cao, S.
    Zhang, L.
    Xu, J.
    Zhang, B.
    Zhang, X.
    Wang, H.
    Han, B.
    Zhong, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S68 - S68
  • [33] Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    PHARMACOECONOMICS, 2017, 35 (08) : 831 - 844
  • [34] Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
    Min Huang
    Yanyan Lou
    James Pellissier
    Thomas Burke
    Frank Xiaoqing Liu
    Ruifeng Xu
    Vamsidhar Velcheti
    PharmacoEconomics, 2017, 35 : 831 - 844
  • [35] Cost-effectiveness of liquid biopsy for molecular profiling of newly diagnosed advanced non-squamous NSCLC in an Asian population
    Tan, Aaron C.
    Liu, Sibo
    Graves, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 178 - 178
  • [36] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
    Chen, Ya
    Wang, Yanan
    Yang, Zhengyu
    Hu, Minjuan
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Liting Wang
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Sini Li
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 4354 - 4365
  • [38] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Wang, Liting
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Li, Sini
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4354 - 4365
  • [39] First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials
    Doherty, M.
    Delos Santos, S.
    Rahmadian, A. Putri
    Chan, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S465 - S466
  • [40] Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis
    Mingjun Rui
    Yingcheng Wang
    Yunfei Li
    Zhengyang Fei
    BioDrugs, 2024, 38 : 157 - 170
12345